Drug Type shRNA |
Synonyms- |
Target |
Action inhibitors |
Mechanism FasR inhibitors(Apoptosis-mediating surface antigen FAS inhibitors), TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Metastatic castration-resistant prostate cancer | Preclinical | United States | 05 Nov 2025 |





